ANEB

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-24.5K ExitQ1 2026 $24k $0.7876 $0.33
Jim SimonsRenaissance Technologies $-25.3K ExitQ1 2026 $25k $0.7876 $0.33
Jim SimonsRenaissance Technologies $-45.9K TrimQ4 2025 $46k $2.28 $0.33
Ken GriffinCitadel Advisors $-36.0K ExitQ3 2025 $36k $2.35 $0.33
Ken GriffinCitadel Advisors $21.5K AddQ2 2025 $22k $1.14 $0.33

Insider Trades

Name	Value	Action	Price	Last Price
English Aron R.Director, 10 Percent Owner: $10M10.1M shares BuyDec 23, 2024 $0.99 $0.33

Trade ANEB

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a biotechnology firm currently in the clinical trial phase, committed to devising and introducing treatments for individuals affected by severe cannabinoid poisoning and various forms of substance dependency. Its leading experimental drug, ANEB-001, is a small molecule engineered to counteract cannabinoid receptors, specifically targeting both cannabinoid intoxication and overdose. The company was founded in 2020 and maintains its headquarters in Lakeway, Texas.

CEO: Richard Anthony Cunningham
IPO Date: May 7, 2021

Market Data

Open: $0.4226
High: $0.46
Low: $0.39
Volume: 100
Avg Volume: 5.7K
52W High: $3.42
52W Low: $0.30

Valuation

Market Cap: $15.9M
Enterprise Value: $6.9M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$6.3M
Revenue: $0
Net Income: -$8.5M
Cash: $11.6M
Debt: $0

Events

EarningsSep 23

EPS est. -0.1